Novo Nordisk Long Term Debt 2010-2024 | NVO

Novo Nordisk long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Novo Nordisk long term debt for the quarter ending March 31, 2024 was $2.441B, a 30.2% decline year-over-year.
  • Novo Nordisk long term debt for 2023 was $2.981B, a 13.44% decline from 2022.
  • Novo Nordisk long term debt for 2022 was $3.443B, a 66.99% increase from 2021.
  • Novo Nordisk long term debt for 2021 was $2.062B, a 364.62% increase from 2020.
Novo Nordisk Annual Long Term Debt
(Millions of US $)
2023 $2,981
2022 $3,443
2021 $2,062
2020 $444
2019 $451
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $94
2010 $90
2009 $182
Novo Nordisk Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $2,441
2023-12-31 $2,981
2023-09-30 $2,909
2023-06-30 $2,837
2023-03-31 $3,497
2022-12-31 $3,443
2022-09-30 $3,266
2022-06-30 $3,457
2022-03-31 $3,632
2021-12-31 $2,062
2021-09-30 $1,966
2021-06-30 $2,020
2021-03-31 $459
2020-12-31 $444
2020-09-30 $414
2020-06-30 $404
2020-03-31 $423
2019-12-31 $451
2019-09-30 $436
2019-06-30 $448
2019-03-31 $488
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30 $85
2012-06-30 $87
2012-03-31 $90
2011-12-31 $94
2011-09-30 $95
2011-06-30 $97
2011-03-31 $92
2010-12-31 $90
2010-09-30 $172
2010-06-30 $174
2010-03-31 $180
2009-12-31 $182
2009-09-30 $185
2009-06-30 $179
2009-03-31 $177
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $596.438B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $744.339B 107.58
Johnson & Johnson (JNJ) United States $364.058B 14.46
Merck (MRK) United States $331.772B 60.36
AbbVie (ABBV) United States $290.591B 15.02
AstraZeneca (AZN) United Kingdom $239.075B 20.78
Novartis AG (NVS) Switzerland $210.205B 14.90
Pfizer (PFE) United States $161.668B 20.09
Sanofi (SNY) $122.484B 11.56
Innoviva (INVA) United States $1.007B 7.07